DOCSLIB.ORG

Download Move Magzter App from Android & Apple Store

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Move Magzter App from Android & Apple Store Terminals Tussle Major Port Authority Emerging Out of Edible Oil Imports on for Cargo Bill 2020 Congestion Slippery Grounds south asia’s premier maritime business magazine R100 JUL-SEP 2021 WWW.MARITIMEGATEWAY.COM RNI NO: TELENG/2009/30633 POSTAL REGISTRATION NO: HD/1137/2019-2021 DATE OF PUBLICATION: 01/08/2021 DATE OF POSTING: 05/08/2021 RIDING THE LCL BOOM VAISHNAV SHETTY EXECUTIVE DIRECTOR, ECU WORLDWIDE LOGISTICS IN THE COMBAT AGAINST COVID-19 Logistics service providers have braved the pandemic and maintained the supply chain against all the odds, while exercising necessary precautions to ensure both medical supplies and essentials of life are delivered in-time Grain Pneumatic Ship Un-loader TCI Supply Chain Solutions Negative pressure conveying, small clearance volume fully enclosed conveying, no pollution ....enabling your Logistics Strategy from Design to Execution W A IR R The core values offered by TCI Supply Chain solutions are A E , H A O Network Design for production, aftermarket or demand E U S S , fulfillment. We bring to the table Supply Chain E physical & digital expertise L I Management A to integrate your suppliers/customers into a seamless R , D network enhancing your productivity & control over your A O R : supply/demand chain. S C I L T O S G I Key Industry Verticals: EXCELLERATE YOUR SIMPLIFI YOUR INNOVATE YOUR SECURE YOUR IMMUNIZE YOUR PERPETUATE AUTO SUPPLY CHAIN OMNI CHANNEL RETAIL HI-TECH SUPPLY CHAIN CHEMICAL SUPPLY CHAIN PHARMA SUPPLY CHAIN YOUR BUSINESS Omni-Channel Auto Hi-tech Telecom Chemical Pharma RMS Retail Shipyard/Material Yard/Works Solutions Muti-industry and worldwide experience production Years of expertise and accumulated know-how Services: BRA ND S UND ER Supply Chain Production Finished Goods Warehouse Multimodal Value Added Consultancy Logistics Logistics Management (DC/FC) Logistics Services Offshore Engineering Lifting Solutions About TCI : • Moving 2.5 of India’s GDP by Value of Cargo • 12 Million sq. ft. of warehousing space • 1400 Professional、Efficient and Safe Customized according to your actual needs Branch offices • Over 12000 Trucks in Operations • 6000+ Strong and Dedicated Workforce • Fleet of 7 Cargo Ships • CHA License • ISO Certified • Public Listed TEL +86-21-63333037 +86-513-80108718 Email [email protected] A division of Transport Corporation of India Ltd. TCI House, 69 Institutional Area, Sector - 32, Gurugram - 122 001, Haryana, India. Tel: +91-124-2381603 | Fax: +91-124-2384085, Email: [email protected] | Website: www.tciscs.com Join the conversation online #GENMA Solution Find Us on Bulk Material Handing Solutions Environmental protection, w w w . g e n m a s o l u t i o n . c o m Energy saving, Efficiency and fafety FROM THE EDITOR ARE INDIAN SEAFARERS BEING TARGETED? India had recently launched an aggressive vaccination programme in the country to counter Covid pandemic and the impending third wave, with three of its own developed vaccines, Covaxin, Covishield and Corbevax. Most of the seafarers in India have been given Covaxin, a two-shot vaccine developed by Bharat Biotech, which is however, not yet approved by the World Health Organization (WHO). Citing this as the reason some of the shipping companies have denied permission for Indian seafarers who have received Covaxin. Of late, the All India Seafarer & General Workers Union has written a letter to the Union Minister for Ports, Shipping and Waterways, Sarbananda Sonowal alleging that China has not been allowing entry of ships to its ports with Indian crew on board since March 2021. The workers union has sought the central government’s help in resolving the ‘unofficial ban’ The unofficial imposed by China on vessels entering its ports with Indian seafarers. This is not the first instance as some Indian sailors faced a similar issue earlier in 2021 when China did not allow ban imposed two foreign ships with them onboard to berth at its port. by China has The unofficial ban imposed by China has affected about 20,000 Indian seafarers facing threat of affected about job loss, as companies are not recruiting them for the China-bound ships. 20,000 Indian China has clarified that the restrictions are not targeted on ships crewed by Indian seafarers, but seafarers. said that some measures are directed only to control the impending third wave of pandemic, and to ease the supply chain disruptions. The Chinese Ministry of Transportation confirmed recently that it was blocking crew changes for at least 30 days from certain crewing agencies and management companies, after positive cases of the virus were discovered among crewmembers coming ashore. However, the Maritime Association of Shipowners, Shipmanagers and Agents (MASSA), is in regular touch with the Indian Shipping Ministry regarding crew change challenges faced by Indian seafarers and is in dialogue with the concerned states to find a resolution to this stalemate. Abhijeet Sangle, Working President of the All India Seafarer and General Workers Union, claimed it to be China’s tactic to isolate Indian seafarers in order to provide better prospects to its sailors. The central government and the Director General of Shipping of India must deal with the issue seriously and sort it out with the Chinese counterparts, as 80 per cent of seafarers on various ships come from India and without them the shipping industry which is already witnessing several supply chain disruptions may get into troubled waters. R Ramprasad Editor-in-Chief and Publisher [email protected] JULY-SEPTEMBER 2021 ∙ MARITIME GATEWAY 3 NOW YOU CAN READ YOUR FAVORITE MAGAZINE ON THE DOWNLOAD MOVE MAGZTER APP FROM ANDROID & APPLE STORE CONNECT WITH MG FOLLOW US ON @MARITIMEGATEWAY EDITORIAL ADVISORY EDITOR AND PUBLISHER BOARD R RAMPRASAD, [email protected] SABYASACHI HAJARA GENERAL MANAGER - OPERATIONS FORMER CHAIRMAN, SCI RAVI TEJA, [email protected] CHAIRMAN EDITORIAL ADVISORY BOARD ASSOCIATE EDITORS BILL SMART CHIEF EXECUTIVE, BENGAL TIGER LINES OMER AHMED SIDDIQUI, [email protected] NARASIMHA RAO, [email protected] JULIAN MICHAEL BEVIS FORMER SENIOR DIRECTOR, GROUP RELATIONS, SOUTH ASIA DESIGN CONSULTANT A.P.MOLLER-MAERSK VIJAY MASA, CREATIVE CLICKS CAPT DEEPAK TEWARI MANAGER - MARKETING & SALES CHAIRMAN, CONTAINER SHIPPING LINES ASSOCIATION (CSLA) NATIONAL & INTERNATIONAL SATISH SHETTI, [email protected] +91 99207 05534 ADARSH HEGDE JOINT MANAGING DIRECTOR ADMINISTRATION ALLCARGO LOGISTICS KISHORE P, CHIEF MANAGER, GENERAL ADMINISTRATION MADHUKAR, MANAGER, [email protected] +91 93937 68383 P JAIRAJ KUMAR CHAIRMAN & MD OCEAN SPARKLE LIMITED DIGITAL MEDIA VINAY SHARDUL THACKER PARTNER, MULLA & MULLA & FINANCE CRAIGIE BLUNT & CAROE RAKESH U DHRUV KOTAK MANAGING DIRECTOR, JM BAXI GROUP MANISH SAIGAL MD, ALVAREZ & MARSAL JASJIT SETHI CEO, TCI SUPPLY CHAIN SOLUTION CAPT DINESH GAUTAMA PRESIDENT, NAVKAR CORPORATION LIMITED Maritime Gateway is printed by R Ramprasad published by R Ramprasad on behalf of Gateway Media Pvt Ltd, D.No. 6-2-984, #407, 5th Floor, Pavani Plaza, Khairatabad, Hyderabad – 500 004, Telangana, India. CAPT SANJEEV RISHI ADVISOR, WORLDS WINDOW INFRASTRUCTURE & LOGISTICS PVT LTD Printed at M/s PVB Printers, 11-5-418/A, Ground Floor, Skill Adobe Apartment, Redhills, Lakdikapool, Hyderabad - 500004. Published at Gateway Media Pvt Ltd, D.No. 6-2-984, #407, 5th Floor, Pavani Plaza, Khairatabad, Hyderabad – 500 004, Telangana, India. NAVIN PASSEY MANAGING DIRECTOR, WALLEM REGD. OFFICE: D.No. 6-2-984, #407, 5th Floor, Pavani Plaza, Khairatabad, Hyderabad – 500 004, Telangana, India. SHIPMANAGEMENT (INDIA) PVT LTD CIN: U74900TG2007PTC054344 EDITOR: R Ramprasad Views expressed in the articles are those of the writer(s) and may not be shared by the editor or members of the editorial board. Unsolicited material will not be returned. COPYRIGHT: No material published here should be reproduced in any form without prior written permission from Gateway Media. FEEDBACK: Readers are advised to send all feedback and comments to [email protected] MARITIME GATEWAY ∙ JULY-SEPTEMBER 2021 4 Your Business. Our Passion. Our constant further development serves the goal of being able to handle your cargo even more efficiently in the future. liebherr.com Liebherr maritime cranes CONTENTS VOLUME 13 | ISSUE 05 | JULY-SEPTEMBER 2021 LOGISTICS IN THE COMBAT AGAINST COVID-19 12 Cover Story Logistics service providers have braved the 10 23 pandemic and maintained the supply chain MAJOR PORT AUTHORITY BILL 2020 LOGISTICS against all the odds, while exercising necessary Will it change the culture of Picking up the precautions to ensure both medical supplies and major ports? Gauntlet essentials of life are delivered in-time The new legislation is completely We have faced two waves of the Interviews silent about the operational pandemic, while in the first wave and financial efficiency and the entire country was caught the accountability of the board off-guard, but in the second wave members towards the performance. the response was stronger, wise There are no provisions for the and effective. accountability part. 25 Vaishnav Shetty Executive Director, ECU Worldwide 30 21 DEMURRAGE AND DETENTION SEAFARERS CHARGES Seafarers - A drag on the shippers The front line warriors The current supply chain disruption In spite of offering yeoman services is resulting in high detention and 29 during the pandemic to ensure the demurrage charges, which is an Amit Gupta supply chain remains unbroken, offshoot of a sudden surge in Managing Director, Suraj Informatics seafarers have been severely demand and port congestion. strained while performing their Others duties 27 NORTHEAST INDIA: Opening up trade and connectivity 32 CHITTAGONG PORT: Emerging out of congestion 34 EDIBLE OIL: Edible oil imports on slippery ground 36 FUTURE FUELS: Decarbonising ocean trade 39 PORTS: Shielding against natural calamities 41 TERMINALS: Terminals tussle for cargo MARITIME GATEWAY ∙ JULY-SEPTEMBER 2021 6 POINTNUMBERS BLANK & GRAPHS “The positive externalities of GST “Given their huge potential such as unified market, removal advantages, there is a need for of cascading and improved Maharashtra to focus on biofuels competitiveness of goods and and alternate fuels.
Load more

Recommended publications
  • What Do We Know About India's Covaxin Vaccine?
    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
    [Show full text]
  • 0 January to July 2021
    0 www.journalsofindia.com January to July 2021 SCIENCE & TECH ............................................................................................................................................................... 6 1. REUSABLE LAUNCH VEHICLE TECHNOLOGY DEMONSTRATION PROGRAMME(RLV-TD) ................................................. 6 2. GAGANYAAN MISSION ..................................................................................................................................................... 6 3. MARS ORBITER MISSION (MOM) ..................................................................................................................................... 6 4. CHANDRAYAAN MISSION................................................................................................................................................. 7 5. SOLAR MISSION ............................................................................................................................................................... 8 6. ARTEMIS ACCORD ............................................................................................................................................................ 9 7. NATIONAL MISSION ON INTERDISCIPLINARY CYBER-PHYSICAL SYSTEM (NMICPS) ....................................................... 10 8. SMART ANTI-AIRFIELD WEAPON (SAAW) ...................................................................................................................... 10 9. AQUAPONICS ................................................................................................................................................................
    [Show full text]
  • COVID-19 Summary of Guidelines
    [3] Table of Contents 1. Containment Plan for Large Outbreaks: Novel Corona Virus Disease 2019 (COVID-19 ............................... 7 2. Social Stigma Associated with COVID-19....................................................................................................... 7 3. Guidelines for Dialysis with reference to COVID 19 Infection ....................................................................... 7 4. Guidance document on appropriate management of suspect/ confirmed cases of COVID 19......................... 7 5. COVID - 19 testing laboratories approved and supported by ICMR as on 07/04/2020 ................................... 8 6. Railways meet half initial target in a quick time ............................................................................................... 8 7. DST supported healthcare startup developing rapid test for detection of COVID-19 .................................... 8 8. Check urgently the virus of misinformation on COVID-19: Vice President .................................................... 8 9. Guidelines for Quarantine facilities................................................................................................................. 9 10. Advisory on use of Homemade Protective Cover for Face & Mouth .............................................................. 9 11. Advisory to start rapid antibody-based blood test for COVID-19 .................................................................. 9 12. MHA writes to States/UTs to ensure smooth Disbursal of Money to beneficiaries
    [Show full text]
  • Ifs Recommendations for Covid 19 Vaccination Before Art
    16 – 17 JULY 2020 PRAGATI MAIDAN - DELHI INDIAN FERTILITY SOCIETY IFS RECOMMENDATIONS FOR COVID 19 VACCINATION BEFORE ART IFS SECRETARIAT +91 11 40018184 +91 9899308083 indianferlitysociety [email protected] www.indianferlitysociety.org indianferlitysociety 302, 3rd Floor, Kailash Building, ifsdelhi 26, Kasturba Gandhi Marg, C.P. New Delhi - 110001 Cosmo Tech is the Most Important Trade show for the Suppliers to EXPAND Strengthen Increase Multiply Profits New Markets Pan New Market Customer Base India & World Customer Soaring Boost Network Brand Sales Brand Recall Value with the Industry Visibility ORGANIZED BY CALL EMAIL +91 9971811937 [email protected] +91 9999302797 [email protected] +91 9811141938 [email protected] W W W .C O SMO TEC HEXPO IND IA .C O M Dr. Sudha Prasad Dr. Neena Malhotra President Secretary General Indian Fertility Society Indian Fertility Society Director, Matritava Advanced IVF & Professor, ART Centre, Department of Training Cenre, Vasant Vihar, New Delhi Obstetrics and Gynaecology, AIIMS, New Delhi Dr. Sonia Malik Dr. Kuldeep Jain Past President Indian Fertility Society, Past President Indian Fertility Society, Director & Nova Southend Fertility & Director, KJIVF New Delhi IVF Delhi NCR Dr. KU Kunjumoideen Dr. A K Pandey Joint Secretary Indian Fertility Society, Dean Academics &. Co Ordinator Director ARMC IVF Calicut. Molecular Lab. ESI Medical college Faridabad Dr. Charu Jandial Dr. Sumita Aggarwal Member IFS, Consultant, Member IFS, Fellow, Nova Southend Fertility & IVF Delhi NCR Nova Southend Fertility & IVF Delhi NCR Introduction The coronavirus pandemic has wreaked havoc on life In these trying mes, as sociees are gradually trying to and healthcare globally. According to WHO database as return to a state of normalcy, it is also important to on 7th June 2021, there have been 173 million consider sexual and reproducve health of people.
    [Show full text]
  • Bcpct]Ttsbc^Prc U^A Dq[XRV^^S
    6 < %()(=#%% 53%7==,>3='$()6(=#%% (#-'>3='$()6(=#%% $'()"*$+&,- %( !"# $$%& 2(*3-% (566)(37)% 3 0 4 $5 3 $1 2 0 .8 9 8 ++0 0 .:; . !" . / 01 $ %'( $) '# *' it for the last eight to nine notable achievements to its months, “where is the UN in name in the 75 years of its aking a strong case for a this joint fight. Where is the experience, including the pre- Msignificant role for India effective response.” vention of a third world war, in the United Nations, Prime Focussing on a more “we can’t deny terrorist attacks 0 Minister Narendra Modi on prominent role for India in the shook the world”. Saturday stressed the need for UN and fight against corona, “We have successfully ne of the oldest partners changes in the international the Prime Minister avoided avoided a third world war but Oof the BJP — the body and questioned its posi- making any reference to ongo- we cannot deny many wars Shiromani Akali Dal — which tion in fighting the coron- ing tension at the Line of happened, many civil wars has been with it through thick avirus pandemic. Actual Control (LAC) and happened. Terrorist attack and thin for decades, finally He also assured the global frosty ties with Pakistan in his shook the world. Blood was quit the National Democratic Q community that India will pro- 20-minute speech. He also did spilled. Those were killed were Alliance (NDA) on Saturday, vide corona vaccine to the not respond to Pakistan Prime like you and me. Children left signaling a complete political world as it is the world’s biggest Minister Imran Khan’s remarks the world prematurely,” he said.
    [Show full text]
  • In 2020, India Dealt with the First Wave of COVID-19 Pandemic With
    PREFACE n 2020, India dealt with the first wave of COVID-19 pandemic with collective measures, Iscientific approach, and awareness. Undoubtedly the second wave of the pandemic is testing our patience and the extent to which we can all tolerate its fangs. The impact of the second wave has seen shortage of medical oxygen across the nation. But, the intelligent use of technology and well-planned resource allocation to tackle the new wave of the pandemic has been dealt with at a war-footing. The current edition, COVID 2021: Nation’s S&T Efforts Against COVID-19, has been compiled to inform our readers and strengthen the usefulness of any published information. This edition contains compilation and coverage of information related to the capacity enhancement of medical oxygen, start-up spotlights, research contributions, and so on. To bridge the gap among scientific contributions, leadership and administrative efforts, and the perspective of the general public, Vigyan Prasar is continuously reaching out to its audiences in the shape of a regular e-newsletter, taking its mandate of science communication, popularisation and extension to the next level. Our effort is firmly based on the fact that “Science gathers knowledge faster than society gathers wisdom”. The steady increase in the number of recoveries and the significant and continuous decrease in positivity rate provide us the much-needed assurance that this may be the outcome of improving the health infrastructure and making health the cornerstone at the policy level. We wish an engaging reading to our audiences across all strata of the society and look forward to suggestions and feedback at [email protected].
    [Show full text]
  • HYDERABAD, SATURDAY, JUNE 5, 2021; PAGES 12 `3 RNI No
    Follow us on: @TheDailyPioneer facebook.com/dailypioneer HYDERABAD, SATURDAY, JUNE 5, 2021; PAGES 12 `3 RNI No. TELENG/2018/76469 Established 1864 Published From HYDERABAD DELHI LUCKNOW BHOPAL RAIPUR CHANDIGARH BHUBANESWAR RANCHI DEHRADUN VIJAYAWADA *LATE CITY VOL. 3 ISSUE 226 *Air Surcharge Extra if Applicable www.dailypioneer.com Managed second wave, P RBI keeps interest rates unchanged P ‘Keen on signing scripts P ‘very well’; ready for 3rd: NITIA that are fun 5 announces measures to aid economy 8 entertaining, challenging’ 11 In brief IMPORT VACCINE, SAVE Petrol crosses Etela quits Assembly, TRS Pfizer vaccine for Rs 100/litre Ex-minister confirms he would be joining BJP; 12-15 age group PEOPLE, KTR TELLS CENTRE mark in TS, AP launches no-holds-barred attack on KCR gets nod in the UK ML MELLY MAITREYI ritain's medicines regulator said PNS n HYDERABAD PNS n NEW DELHI n HYDERABAD Friday the Pfizer/BioNTech B vaccine is safe for adolescents Minister KT Rama Rao on Friday After Rajasthan, Madhya Pradesh Former minister Etela Rajender let aged 12 to 15 after a "rigorous review", targeted the Centre again for its and Maharashtra, petrol price the suspense over his political following similar assessments in the “bungling” on Covid-19 vaccina- has crossed the Rs 100-per-litre future hang for some time even as EU and US."We have carefully tion and demanded that it imme- mark in almost all districts of AP he resigned from the Membership reviewed clinical trial data in children diately import vaccines from coun- and parts of Telangana after fuel of the State Legislative Assembly aged 12 to 15 years and have tries that are sitting on a huge prices were again hiked on Friday.
    [Show full text]
  • COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021
    CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 5th April, 2021 I. Overview of Development and Regulatory Approvals: • 85 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 13 vaccines have received regulatory approvals in various countries, and 16 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • 4 vaccines have been approved by WHO for Emergency Use Listing: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), and Janssen-Cilag. • 4 additional vaccines are expected to be approved by WHO in April – Tables 1 and 3. • There are 3 additional vaccines being considered by WHO but these are at the stage of submitting expressions of interest: Bharat Biotech, Clover Biopharmaceuticals-GSK + Dynavax, and BioCubaFarma (Cuba). • The WHO Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations and background documents are available for vaccines by: Moderna, Pfizer-BioNTech, AstraZeneca-Oxford and Janssen-Cilag at SAGE Interim Guidance. The recommendations provide guidance on the use the vaccines, including use in various groups. • Reports of rare clotting events among vaccinees continue to be assessed by various regulators. The EU's European Medicines Agency (EMA) has stated that there was no evidence to support decisions by regulators to restrict the use of Oxford-AstraZeneca vaccines in some age groups. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made.
    [Show full text]
  • Lok Sabha Secretariat (LARRDIS) New Delhi
    Lok Sabha Secretariat (LARRDIS) New Delhi BACKGROUND NOTE on “Status of COVID - 19 Vaccine production in India” (For the use of the Standing Committee on Chemicals and Fertilisers) October 2020 ____________________________________________________________________________ The brief note is intended to serve only as a background aid to the Standing Committee on Chemical and Fertilisers. It is for restricted circulation and not for publication in any form. [Prepared by the Educational & Scientific Affairs Wing of the R&I Division. Officers associated with the preparation - Babulal Naik, Additional Director;Ms. Namita Kumari, RO; supervised by Shri Pradosh Panda, Director. Feedback is welcome and may be sent to [email protected]] Status of COVID - 19 vaccine production in India LARRDIS October 2020 Introduction India has the world's second largest coronavirus cases after the United States. However, after 8 months since the pandemic hit the country, the rising per day COVID cases curve has started to decline, especially at a time when a possible launch of coronavirus vaccine is being hoped by many by early 2021. COVID-19 is a new strain of coronavirus that has not been previously identified in humans. The COVID-19 is the cause of an outbreak of respiratory illness first detected in Wuhan, Hubei province, China. Since December 2019, cases have been identified in a growing number of countries. The Indian government and private firms have stepped up efforts to develop a vaccine to halt the spread of COVID-19 which has claimed over 118,567 lives till 25th October 2020 in the country1. Source : Ministry of Health and Family Welfare dated 27 th Oct 2020 The whole world is waiting eagerly for an effective vaccine to fight the coronavirus pandemic.
    [Show full text]
  • V.3 1/25/2021 COVID-19 Vaccine FAQ Sheet
    COVID-19 Vaccine FAQ Sheet (updated 1/25/2021) The AST has received queries from transplant professionals and the community regarding the COVID-19 vaccine. The following FAQ was developed to relay information on the current state of knowledge. This document is subject to change and will be updated frequently as new information or data becomes available. What kinds of vaccines are available or under development to prevent COVID-19? There are currently several vaccine candidates in use or under development. In the United States, the Government is supporting six separate vaccine candidates. Several other vaccines are also undergoing development outside of the United States government sponsorship and further information can be found here: • NYTimes Coronavirus Vaccine Tracker: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine- tracker.html • Washington Post Vaccine Tracker: https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update- coronavirus/ The types of vaccines are as follows (January 25, 2021) 1: Table 1: Vaccines Under Development Vaccine Type Compound Name Clinical Trial Notes [Sponsor] Phase mRNA mRNA-1273 Phase 3 Emergency use in [Moderna] U.S., E.U., other countries Approved in Canada BNT162b2 [Pfizer] Phase 2/3 Emergency use in U.S., E.U., other countries Also approved in Canada and other countries Replication- AZD1222 Phase 2/3 Emergency use in defective [AstraZeneca] Britain, India, other adenoviral vector countries (not U.S.) Ad26.COV2.S Phase 3 [Janssen] v.3 1/25/2021 Recombinant- NVX-CoV2373 Phase 3 subunit-adjuvanted [Novavax] protein Recombinant SARS- Phase 1/2 CoV-2 Protein Antigen + AS03 Adjuvant [Sanofi Pasteur/GSK] Inactivated CoVaxin [Bharat Phase 3 Emergency Use in coronavirus Biotech] India BBIBP-CorV Phase 3 Approved China, [Sinopharm] Bahrain, UAE; Emergency use elsewhere (not U.S.) Both of the mRNA SARS-CoV-2 vaccines (Moderna, Pfizer) have been approved by Emergency Use Authorization by the U.S.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St
    Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St. Louis to advance COVID-19 Intranasal Vaccine Technology Hyderabad, India, 23 September 2020: Vaccine Innovator, Bharat Biotech announces today, a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp- adenovirus, single dose intranasal vaccine for COVID-19. Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe. While the Phase I trials will take place in Saint Louis University’s Vaccine & Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad. We are proud to collaborate on this innovative vaccine. We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive. Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world.” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated. This intranasal vaccine candidate has shown unprecedented levels of protection in mice studies; the technology and data having been recently published in the prestigious scientific journal Cell and in an editorial in Nature.
    [Show full text]